Corient Private Wealth LP Makes New Investment in HealthEquity, Inc. $HQY

Corient Private Wealth LP purchased a new stake in HealthEquity, Inc. (NASDAQ:HQY) in the 2nd quarter, HoldingsChannel.com reports. The fund purchased 27,415 shares of the company’s stock, valued at approximately $2,476,000.

Other institutional investors have also recently made changes to their positions in the company. Oxbow Advisors LLC bought a new position in HealthEquity in the 1st quarter worth about $3,147,000. Deutsche Bank AG purchased a new stake in shares of HealthEquity in the 2nd quarter valued at about $11,986,000. Maridea Wealth Management LLC bought a new stake in shares of HealthEquity during the 2nd quarter valued at about $2,753,000. Westfield Capital Management Co. LP boosted its position in shares of HealthEquity by 13.7% during the 4th quarter. Westfield Capital Management Co. LP now owns 1,952,452 shares of the company’s stock valued at $178,864,000 after acquiring an additional 235,794 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd purchased a new position in shares of HealthEquity during the fourth quarter worth about $4,381,000. Institutional investors own 99.55% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on HQY shares. Citigroup restated a “market outperform” rating on shares of HealthEquity in a research report on Friday, August 28th. Telsey Advisory Group set a $111.00 target price on shares of HealthEquity in a research report on Friday, August 28th. Wall Street Zen raised shares of HealthEquity from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Weiss Ratings raised shares of HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, June 5th. Finally, Barrington Research restated an “outperform” rating and set a $110.00 price objective on shares of HealthEquity in a research report on Friday, May 22nd. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $111.87.

Insiders Place Their Bets

In related news, Director Adrian T. Dillon sold 7,632 shares of HealthEquity stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $104.61, for a total value of $798,383.52. Following the transaction, the director owned 62,395 shares in the company, valued at $6,527,140.95. This trade represents a 10.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Henry Fiore sold 2,470 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $95.00, for a total transaction of $234,650.00. Following the completion of the sale, the executive vice president directly owned 56,643 shares of the company’s stock, valued at $5,381,085. This represents a 4.18% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 12,456 shares of company stock worth $1,256,664. 1.60% of the stock is owned by corporate insiders.

HealthEquity Price Performance

Shares of HealthEquity stock opened at $98.54 on Thursday. The firm has a market capitalization of $8.15 billion, a PE ratio of 35.57, a price-to-earnings-growth ratio of 1.53 and a beta of 0.22. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.47. HealthEquity, Inc. has a 12 month low of $72.76 and a 12 month high of $107.62. The business’s 50-day moving average price is $98.91 and its 200-day moving average price is $88.38.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Thursday, August 27th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.19 by $0.05. The firm had revenue of $350.73 million for the quarter, compared to the consensus estimate of $349.22 million. HealthEquity had a net margin of 17.36% and a return on equity of 15.33%. The firm’s revenue for the quarter was up 95.5% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. Sell-side analysts forecast that HealthEquity, Inc. will post 3.93 EPS for the current fiscal year.

HealthEquity Profile

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.